UPDATE: Piper Jaffray Starts Moderna (MRNA) at Overweight

Needham & Company Starts Moderna (MRNA) at Buy

Needham & Company analyst Alan Carr initiates coverage on Moderna (NASDAQ: MRNA) with a Buy rating and a price target of $28.00.

Carr commented, "Moderna is leveraging an mRNA drug/ drug delivery platform to generate an extensive pipeline across oncology, infectious diseases, cardiology, and rare... More

BofA/Merrill Lynch Starts Moderna (MRNA) at Buy

BofA/Merrill Lynch analyst Ying Huang initiates coverage on Moderna (NASDAQ: MRNA) with a Buy rating and a price target of $20.00.

For an analyst ratings summary and ratings history on Moderna click here. For more ratings news on Moderna click here.

Shares of Moderna closed at $15.27 yesterday.

Oppenheimer Starts Moderna (MRNA) at Outperform

Oppenheimer analyst Leah Rush Cann initiates coverage on Moderna (NASDAQ: MRNA) with a Outperform rating and a price target of $27.00.

For an analyst ratings summary and ratings history on Moderna click here. For more ratings news on Moderna click here.

Shares of Moderna closed at $15.27 yesterday.

Goldman Sachs Starts Moderna (MRNA) at Buy

Goldman Sachs analyst Salveen Richter initiates coverage on Moderna (NASDAQ: MRNA) with a Buy rating and a price target of $25.00.

For an analyst ratings summary and ratings history on Moderna click here. For more ratings news on Moderna click here.

Shares of Moderna closed at $15.27 yesterday.

Morgan Stanley Starts Moderna (MRNA) at Overweight

Morgan Stanley analyst Matthew Harrison initiates coverage on Moderna (NASDAQ: MRNA) with a Overweight rating and a price target of $29.00.

For an analyst ratings summary and ratings history on Moderna click here. For more ratings news on Moderna click here.

Shares of Moderna closed at $15.27 yesterday.

JPMorgan Starts Moderna (MRNA) at Overweight

JPMorgan analyst Cory Kasimov initiates coverage on Moderna (NASDAQ: MRNA) with a Overweight rating and a price target of $22.00.

For an analyst ratings summary and ratings history on Moderna click here. For more ratings news on Moderna click here.

Shares of Moderna closed at $15.27 yesterday.

UPDATE: Barclays Starts Moderna (MRNA) at Overweight

(Updated - January 2, 2019 3:29 AM EST)

(updated to correct company name)

Barclays analyst Geoff Meacham initiates coverage on Moderna (NASDAQ: MRNA) with a Overweight rating and a price target of $20.00.

For an analyst ratings summary and ratings history on... More